Switzerland’s Synendos raises CHF 20m for CNS drug developmentSwiss startup Synendos Therapeutics has raised CHF 20 million (almost $22 million) in first-round financing that will be Share XSwitzerland’s Synendos raises CHF 20m for CNS drug developmenthttps://pharmaphorum.com/news/embargo-8am-gmt-12-nov-switzerlands-synendos-raises-chf-20m-for-cns-drug-development/
Pension funds could be game-changer for UK biotechToday could be a major turning point for the UK biotech sector, as changes in government policy could Share XPension funds could be game-changer for UK biotechhttps://pharmaphorum.com/news/pension-funds-game-changer-uk-biotech/
